Loading...
Loading...
ORMP| Name | Value |
|---|---|
| Revenues | 674.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 674.0K |
| Operating Expense | 4,465.0K |
| Operating I/L | -3,791.0K |
| Other Income/Expense | 2,478.0K |
| Interest Income | 2,478.0K |
| Pretax | -1,313.0K |
| Income Tax Expense | -119.0K |
| Net Income/Loss | -1,194.0K |
Oramed Pharmaceuticals Inc. specializes in developing pharmaceutical solutions for diabetes treatment, focusing on orally ingestible capsules for polypeptide delivery. Its flagship product, ORMD-0801, is an orally ingestible insulin capsule that has completed phase II clinical trials for diabetes treatment. The company is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule for type 2 diabetes, and an oral leptin capsule for weight loss treatment. Oramed Pharmaceuticals Inc. generates revenue through the research, development, and potential commercialization of these innovative oral drug delivery solutions for diabetes and related conditions.
